The results of the present study revealed the good prognosis of patients with localized PG-DLBCL treated with rituximab-containing chemotherapy with or without IFRT, and demonstrated that double expression of MYC and BCL2 did not influence patient outcomes. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.